These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20025567)

  • 61. Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence.
    Daniele G; Giordano P; De Luca A; Piccirillo MC; Di Maio M; Del Giudice A; De Feo G; Bryce J; Lamura L; Vecchione A; Normanno N; Perrone F
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):299-307. PubMed ID: 21342047
    [TBL] [Abstract][Full Text] [Related]  

  • 62. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
    J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.
    Moschetta M; Di Pietro G; Ria R; Gnoni A; Mangialardi G; Guarini A; Ditonno P; Musto P; D'Auria F; Ricciardi MR; Dammacco F; Ribatti D; Vacca A
    Eur J Cancer; 2010 Jan; 46(2):420-9. PubMed ID: 19914061
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines.
    Tamura T; Shomori K; Nakabayashi M; Fujii N; Ryoke K; Ito H
    Oncol Rep; 2011 Apr; 25(4):1139-43. PubMed ID: 21249320
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
    Hiraga T; Ueda A; Tamura D; Hata K; Ikeda F; Williams PJ; Yoneda T
    Int J Cancer; 2003 Oct; 106(6):973-9. PubMed ID: 12918079
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Antiresorptive and anti-angiogenetic octacalcium phosphate functionalized with bisphosphonates: An in vitro tri-culture study.
    Forte L; Torricelli P; Boanini E; Gazzano M; Fini M; Bigi A
    Acta Biomater; 2017 May; 54():419-428. PubMed ID: 28238916
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
    Fanale D; Amodeo V; Bazan V; Insalaco L; Incorvaia L; Barraco N; Castiglia M; Rizzo S; Santini D; Giordano A; Castorina S; Russo A
    Oncotarget; 2016 May; 7(20):29321-32. PubMed ID: 27081088
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combined effects of bisphosphonate and radiation on osteosarcoma cells.
    Ryu K; Murata H; Koto K; Horie N; Matsui T; Nishigaki Y; Sakabe T; Takeshita H; Itoi M; Kimura S; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Anticancer Res; 2010 Jul; 30(7):2713-20. PubMed ID: 20683003
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
    Altundag K; Altundag O; Morandi P; Gunduz M
    Urology; 2005 Jan; 65(1):211-2; author reply 212. PubMed ID: 15667906
    [No Abstract]   [Full Text] [Related]  

  • 70. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
    Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
    Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion.
    Woodward JK; Coleman RE; Holen I
    Anticancer Drugs; 2005 Jan; 16(1):11-9. PubMed ID: 15613899
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Bisphosphonate use and risk of colorectal cancer.
    Khalili H; Chan AT
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1208-9. PubMed ID: 23660421
    [No Abstract]   [Full Text] [Related]  

  • 73. Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer.
    Mbese Z; Aderibigbe BA
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206757
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Targeting macrophages: therapeutic approaches in cancer.
    Cassetta L; Pollard JW
    Nat Rev Drug Discov; 2018 Dec; 17(12):887-904. PubMed ID: 30361552
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In vivo distribution of zoledronic acid in a bisphosphonate-metal complex-based nanoparticle formulation synthesized by a reverse microemulsion method.
    Li X; Naguib YW; Cui Z
    Int J Pharm; 2017 Jun; 526(1-2):69-76. PubMed ID: 28455136
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Reverse Microemulsion-Based Synthesis of (Bis)phosphonate-Metal Materials with Controllable Physical Properties: An Example Using Zoledronic Acid-Calcium Complexes.
    Li X; Naguib YW; Valdes S; Hufnagel S; Cui Z
    ACS Appl Mater Interfaces; 2017 Apr; 9(16):14478-14489. PubMed ID: 28252282
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions.
    Fioramonti M; Santini D; Iuliani M; Ribelli G; Manca P; Papapietro N; Spiezia F; Vincenzi B; Denaro V; Russo A; Tonini G; Pantano F
    Oncotarget; 2017 Mar; 8(12):20113-20121. PubMed ID: 28223547
    [TBL] [Abstract][Full Text] [Related]  

  • 78. DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.
    Arbitrio M; Di Martino MT; Scionti F; Agapito G; Guzzi PH; Cannataro M; Tassone P; Tagliaferri P
    Oncotarget; 2016 Aug; 7(33):54028-54050. PubMed ID: 27304055
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells.
    Biray Avci C; Kurt CC; Tepedelen BE; Ozalp O; Goker B; Mutlu Z; Dodurga Y; Elmas L; Gunduz C
    Tumour Biol; 2016 May; 37(5):6673-9. PubMed ID: 26646564
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model.
    Esser AK; Schmieder AH; Ross MH; Xiang J; Su X; Cui G; Zhang H; Yang X; Allen JS; Williams T; Wickline SA; Pan D; Lanza GM; Weilbaecher KN
    Nanomedicine; 2016 Jan; 12(1):201-11. PubMed ID: 26515754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.